2026-04-02 20:03:52
Tyra Biosciences Appoints Julia Rueb as Principal Accounting Officer in 8-K Filing
Expected Stock impact: None Expected
On April 1, 2026, Tyra Biosciences, Inc. announced a leadership change in its financial department through an 8-K filing with the SEC. Julia Rueb has been designated as the company's principal accounting officer, succeeding Alan Fuhrman, who will continue to serve as the chief financial officer. This transition is effective immediately as of April 1, 2026. Julia Rueb, 40, has been with Tyra Biosciences since January 2024, previously holding the position of Vice President of Finance. Her extensive background includes roles as Director and Senior Director of Accounting and Corporate Controller, as well as experience at SOAProjects, Inc. and Ernst & Young LLP. Rueb holds a Master’s degree in Accounting from the University of San Diego and is a Certified Public Accountant. The filing indicates that there are no family relationships between Rueb and any of the company's directors or executive officers. This change is expected to maintain continuity in the company's financial leadership without significant disruption, as Fuhrman remains in his role as CFO. The filing is categorized under Item 5.02, which pertains to the departure and appointment of certain officers, and is considered an administrative update rather than a significant event that would impact the stock price significantly.
